Discover
ORMP
Oramed Pharmaceuticals Inc.
4.61
2 x 3.35
2 x 5.49
bid
ask
-
0.20
4.16%
2 @ 05:47 AM
4.61 +0.00 (0.00%)
| Ytd | 61.75% | |
| 1y | 119.52% |
4.25
day range
4.75
1.98
52 week range
5.19
| Open | 4.75 | Prev Close | 4.81 | Low | 4.25 | High | 4.75 | Mkt Cap | 188.67M |
| Vol | 1.02M | Avg Vol | 276.85K | EPS | 2.60 | P/E | 1.77 | Forward P/E | -29.75 |
| Beta | 1.77 | Short Ratio | 2.60 | Inst. Own | 17.52% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-14 | 50-d Avg | 4.08 | 200-d Avg | 3.26 | 1yr Est | 3.25 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2024-11-07 | 2024-09 | 0.01 | -0.48 | -0.49 | -4900.00% |
| 2024-08-14 | 2024-06 | 0.01 | 0.22 | 0.21 | 2100.00% |
| 2024-05-09 | 2024-03 | 0.02 | 0.04 | 0.02 | 100.00% |
| 2024-03-06 | 2023-12 | -0.12 | -0.08 | 0.04 | 33.33% |
| 2023-11-09 | 2023-09 | -0.09 | -0.08 | 0.01 | 11.11% |
| 2023-08-10 | 2023-06 | -0.11 | -0.03 | 0.08 | 72.73% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2024-09-09 | HC Wainwright & Co. | Upgrade | Neutral | |
| 2024-05-20 | HC Wainwright & Co. | Upgrade | Neutral | |
| 2023-05-17 | Canaccord Genuity | Upgrade | Hold | Hold |
| 2023-01-17 | HC Wainwright & Co. | Downgrade | Buy | Neutral |
| 2023-01-12 | Canaccord Genuity | Downgrade | Buy | Hold |
| 2022-05-16 | Aegis Capital | Upgrade | Buy |
Profile
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes. It has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19 and other novel coronaviruses. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2024-01-29 | AGHION DANIEL | Director | 38.82K | Stock Award(Grant) |
| 2024-11-06 | GABAY AVRAHAM | Chief Financial Officer | 170.04K | Stock Award(Grant) |
| 2024-11-06 | HEXTER JOSHUA | Chairman of the Board | 511.83K | Stock Award(Grant) |
| 2024-11-06 | KIDRON MIRIAM | Officer | 793.67K | Stock Award(Grant) |
| 2024-11-06 | KIDRON NADAV | Chief Executive Officer | 1.95M | Stock Award(Grant) |
| 2024-01-03 | MAYER ARIE PH.D. | Director | 96.13K | Stock Award(Grant) |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | BML Capital Management, LLC | 2.19M | 5.20M | 5.42% |
| 2024-09-29 | Murchinson Ltd. | 1.71M | 4.07M | 4.24% |
| 2024-09-29 | Boothbay Fund Management, LLC | 828.33K | 1.97M | 2.05% |
| 2024-09-29 | Rathbones Group PLC | 289.80K | 689.73K | 0.72% |
| 2024-09-29 | Two Sigma Advisers, LP | 255.60K | 608.33K | 0.63% |
| 2024-09-29 | Renaissance Technologies, LLC | 245.30K | 583.81K | 0.61% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-10-30 | iShares Micro Cap ETF | 84.64K | 201.44K | 0.21% |
| 2024-09-29 | SPDR Portfolio Developed World ex-US ETF | 47.51K | 113.08K | 0.12% |
| 2024-10-30 | Fidelity NASDAQ Composite Index Fund | 25.46K | 60.58K | 0.06% |
| 2024-09-29 | Avantis U.S. Small Cap Equity ETF | 15.44K | 36.74K | 0.04% |
| 2024-09-29 | SPDR (R) Idx Shares-SPDR (R) S&P (R) International Small Cap ETF | 12.54K | 29.85K | 0.03% |
| 2024-07-30 | DFA U.S. Targeted Value Portfolio | 7.51K | 17.88K | 0.02% |
Dividend
| Dividend | Date |
|---|---|
| 0.25 | 2026-01-16 |
Split
| Split | Date |
|---|---|
| 0.08333 : 1 | 2013-01-23 |